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Abstract
Background: Obesity is a major worldwide public health issue. The main respiratory complication stemming from
obesity is obesity hypoventilation syndrome (OHS). Most of the OHS patients diagnosed during an exacerbation are
treated with non invasive ventilation (NIV). Up to date, no prospective study has demonstrated in real life
conditions the feasibility of a systematic protocoled switch of NIV to continuous positive airway pressure (CPAP),
once stability is achieved.
Methods: In this prospective study, we included stable patients with OHS, with moderate to severe concomitant
obstructive sleep apnea (OSA) and without obstructive pulmonary disease, who had been undergoing NIV for more
than 2 months. The following measurements were performed, first with NIV and then after the switch to CPAP:
diurnal arterial blood gas measurements; nocturnal oximetry and capnometry; mean compliance and AHI; measures
of quality of life and quality of sleep.
Results: 22/30 patients accepted to participate in the study and 15/22 patients completed the study. There were
no significant differences for pooled data in diurnal alveolar blood gases, nocturnal capnometry (p = 0.534),
nocturnal oximetry (p = 0.218), mean compliance (p = 0.766), mean AHI (p = 0.334), quality of life or quality of sleep.
Eighty percent of the patients treated in this study favored CPAP over NIV.
Conclusion: This pilot study showed in real life conditions the possibility of a systematic switch of NIV to CPAP, in
most stable patients with OHS, with similar efficacy on diurnal and nocturnal alveolar gas exchange, quality of life
and quality of sleep.
Trial registration: ISRCTN13981084. Registered: 27 February 2017 (retrospectively registered)
Keywords: Obesity hypoventilation syndrome, Non invasive ventilation, Continuous positive airway pressure, Bilevel
positive airway pressure, Obstructive sleep apnea
Background
Obesity is a major worldwide public health issue [1]. The
main respiratory complication stemming from obesity is
obesity hypoventilation syndrome (OHS). OHS was
defined, in 1999, by the American Academy of Sleep Medi-
cine as the association of obesity (BMI ≥ 30 kg/m2); daytime
hypercapnia (paCO2 > 45 mm Hg); and sleep disordered
breathing, after excluding other causes of hypoventilation
[2]. OHS is a frequent condition with the prevalence of
OHS in patients with a BMI ≥ 35 kg/m2 being 31% [3].
OHS is an underdiagnosed and undertreated condition
[3, 4], despite the fact that a treatment with positive airway
pressure improves quality of life and decreases morbidity
in these patients [3, 5]. The application of a positive airway
pressure through noninvasive ventilation (NIV) or
continuous positive airway pressure (CPAP), decreases
mortality in patients presenting with OHS [4, 6, 7].
* Correspondence: sarah.orfanos@gmail.com
1Aix-Marseille University, Faculté de médecine, 27 Boulevard Jean Moulin,
13005 Marseille, France
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Orfanos et al. BMC Pulmonary Medicine  (2017) 17:50 
DOI 10.1186/s12890-017-0391-9
To date, the main unresolved question is to determine
the respective position of NIV and CPAP when treating
these patients. If some studies have attempted to determine
different OHS’s phenotypes to predict the outcome of
CPAP therapy [8–10]; only two studies prospectively com-
pared NIV and CPAP treatment in OHS [5, 11]. To date,
the superiority of NIV over CPAP in the treatment of OHS
has not been proven. However, 26 to 50% of patients suffer-
ing from OHS are diagnosed in an acute setting [7, 8, 11,
12], and most often treated with NIV which remains their
usual ventilatory mode for the rest of their life.
Once stability has been reached, the question then
arises as to whether NIV should be switched to CPAP.
To our knowledge, no prospective trial has evaluated in
real life conditions the feasibility of a protocol switching
stable patients from NIV to CPAP.
The purpose of this study was to test the feasibility and
effect of a standardized protocol, switching patients with
OHS, from NIV to CPAP. We hypothesized that there will
be no difference in efficacy after switching NIV to CPAP,
on AHI, diurnal and nocturnal alveolar gas exchange (day-
time arterial blood gas (ABG), nighttime transcutaneous
oxygen saturation and transcutaneous measurement of
pCO2 (ptCO2)), but also on sleepiness, quality of sleep
and quality of life (Epworth Sleepiness Scale (EPS),
Pittsburgh Sleep Quality Index (PSQI), Severe Respiratory
Insufficiency questionnaire (SRI)).
Methods
Patients
Patients over 18 years old, suffering from OHS, defined
as an association of obesity (BMI ≥ 30 kg/m2) and day-
time hypercapnia (paCO2 > 45 mm Hg), who had been
undergoing NIV for more than 2 months, were prospect-
ively recruited from February 2015 to February 2016 in
the pulmonology wards of the university hospital (hôpi-
tal Nord) and the military hospital (hôpital Laveran) in
Marseille, France. To be included, patients had to be
clinically stable for at least 4 weeks before enrollment in
the study (no hospitalization or emergency admission).
The exclusion criteria were: patients who presented
hypercapnia secondary to other causes (obstructive
pulmonary diseases (FEV1/FVC < 70), interstitial lung
diseases, neuromuscular or chest wall diseases, severe
hypothyroidism or congenital central hypoventilation
syndrome), and patients unable to give informed
consent.
This trial respected the ethical principles of the declar-
ation of Helsinki and was approved by the local ethic
committee of the Assistance Publique Hôpitaux de
Marseille (AP-HM). Written informed consent was ob-
tained from all patients. The use of data was approved
by the Data Privacy Officer of the hospitals (AP-HM).
Study protocol
Patients who had been undergoing NIV for at least the
last 2 month, were prospectively included in the study
by the investigators, during a follow-up outpatient clinic.
During this clinic, the following clinical information
were collected: history of the diagnosis of OHS, occur-
rence of acute exacerbations, NIV settings: brand, mode,
respiratory rate (RR), expiratory positive airway pressure
(EPAP), inspiratory positive airway pressure (IPAP) and
interfaces.
The settings were in accordance with the American
Academy of Sleep Medicine (AASM) recommendations
[13]. NIV settings were optimized in order to avoid
patient-ventilator dyssynchrony and to correct remaining
respiratory events during sleep, according to the recom-
mendations of the somnoNIV group [14].
Quality of life was evaluated using the SRI question-
naire; daytime sleepiness was evaluated using the ESS
questionnaire; and quality of sleep was evaluated using
the PSQI questionnaire.
Finally, an ABG analysis was performed, during the
consultation, between 10 and 12 am in an awake, seated
patient, at rest for at least 10 min.
During one night with NIV, at home, the patient
underwent: (i) nocturnal oximetry using a pulse oxim-
eter (Rescan® software, Resmed®, Australia, New South
Wales, Bella-Vista), on which were calculated the per-
centage of recording time with SaO2 < 90% (RT < 90%)
and the oxygen desaturation index (ODI) (defined as the
number of time per hour the oxygen saturation drops
by ≥ 4%); (ii) nocturnal transcutaneous capnometry using
a transcutaneous capnometer (Tosca 500®, Radiometer®,
Crawley, UK), on which was calculated the mean ptCO2;
(iii) a report of the mean compliance, the median leak,
the mean tidal volume and the mean AHI index of the
last month spent with NIV was extracted (Rescan®
software for Resmed®, Australia New South Wales, Bella-
Vista NIV and Directview® for Philips-Respironics®,
Murrysville, Pennsylvania, USA NIV).
After undergoing these procedures, the patients under-
went NIV withdrawal for seven nights. At the end of this
week, pulmonary function tests (PFT) were performed ac-
cording to the American Thoracic Society and European
Respiratory Society 2005 guidelines [15], and an overnight
polygraphy during spontaneous breathing was performed
(Alice PDx®, Philips-Respironics®, Murrysville, Pennsylva-
nia). Polygraphic recordings were analyzed by a blinded
pulmonologist certified in sleep medicine, respiratory
events were scored manually according to the AASM
2012 manual [16]. The AHI, RT < 90% and ODI on this
polygraphy during spontaneous breathing were reported.
At this stage of the trial, patients exhibiting obstructive
ventilatory disorder (FEV1/FVC < 70) or mild OSA (AHI
< 15/h), were not switched to CPAP and continued their
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treatment with NIV. All the other patients were switched
to CPAP, the settings were as follow: constant pressure,
EPAP 2 cm H2O above the EPAP of the previous NIV to
compensate for the absence of an IPAP on the CPAP, set-
tings were not adjusted until measurements were repeated
more than a month after this switch.
After more than a month with CPAP; SRI, ESS and
PSQI questionnaires were reevaluated. An ABG analysis
was performed in the same conditions as previously de-
scribed. During one night with CPAP, at home, the pa-
tient underwent: (i) nocturnal oximetry; (ii) nocturnal
transcutaneous capnometry; (iii) a report of the mean
compliance, the median leak and the mean AHI index of
the last month spent with CPAP was extracted. (Fig. 1).
As a secondary analysis, we analyzed the characteris-
tics of patients failing NIV and CPAP using Salord et al.
criteria to define failure: more than 30% of recording
time spent below 90% saturation or paCO2 > 45 mm Hg,
to determine if a characteristic could be used as a prog-
nostic factor of ventilation failure [10].
Statistical analysis
Continuous data were expressed in means and SDs and cat-
egorical data were expressed as percentages and absolute.
Normality was assessed using Shapiro-Wilk normality
test. Intra-group changes in variables measured at first
with NIV and after the switch to CPAP were assessed
using paired t-tests or non-parametric Wilcoxon tests
depending on normality.
When comparing two independent groups (NIV failure,
NIV success), unpaired t-tests or non-parametric Mann–
Whitney tests depending on normality were used for
continuous variables and x2 tests for categorical variables.
Results
Study population
Twenty-two patients were included. Five dropped-out
due to unwillingness to be hospitalized for the polygra-
phy prior to the switch to CPAP. Two patients were ex-
cluded prior to the switch, one had an obstructive
syndrome on the PFT, and the other had an AHI < 15/h
on the polygraphy. Fifteen of the 30 patients who were
initially selected, were switched to CPAP (Fig. 2).
Anthropometric characteristics of the patients are
shown in Table 1.
Seven nights after the NIV was discontinued, polygra-
phy of the weaning period showed a high mean AHI
(AHI = 53.5/h ±26.9) and the mean RT < 90% was 21.8%
(24.2) (Table 2).
Regarding settings, all NIV were in spontaneous timed
(ST) mode, mean EPAP was 7.7 ± 1.8 cm H2O, mean
IPAP was 18.3 ± 3 cm H2O, mean back-up RR was 13.9
± 1.8 cycles/min. Two patients received additional oxy-
gen therapy, flow rates were not modified after switching
to CPAP. (Table 3).
Effect of the switch to CPAP on the measured data
There were no significant differences, after the switch to
CPAP, in mean AHI, diurnal and nocturnal alveolar gas
exchanges (diurnal ABG, nocturnal oximetry and trans-
cutaneous capnometry), median leaks and compliance
(Table 4, Fig. 3).
Regarding ESS, SRI and PSQI scores, the only signifi-
cant difference was in the ESS, which was lower after
the switch to CPAP (8.21 ± 5.54 vs 4.29 ± 3.43) (p =
0.004). There were no significant differences in the SRI
and all its subscales and in the PSQI and all its compo-
nents between before and after the switch to CPAP.
(Table 5, Fig. 4).
At the end of the trial, through a self-administered
questionnaire, the patients’ preference for one mode of
ventilation was determined. Twelve patients (80%)
Fig. 1 Study protocol. Definition of abbreviations: OHS: Obesity
Hypoventilation Syndrome; NIV: Non Invasive Ventilation; SRI: Severe
Respiratory Insufficiency questionnaire; PSQI: Pittsburgh Sleep Quality
Index; ESS: Epworth Sleepiness Scale; AHI: Apnea Hypopnea Index;
ABG: Arterial Blood Gas; FEV1: Forced Expiratory Volume in 1 s; FVC:
Forced Vital Capacity; EPAP: Expiratory Positive Airway Pressure;
CPAP: Continuous Positive Airway Pressure
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reported that they preferred CPAP over NIV and wanted
to continue their treatment with CPAP. Two patients
(13%) had no preference. Only one patient wanted to
discontinue CPAP and go back to NIV, despite the fact
that there were no objective criteria of deterioration
during CPAP treatment.
Safety
None of the patients presented with clinical deterior-
ation after more than a month of CPAP and needed to
be switched back to NIV. Two patients were admitted in
the intensive care unit during the trial, due to causes
unrelated to the mode of ventilation. One presented
with acute renal failure complicated by symptomatic
hyperkalemia and the other with left heart failure
secondary to non-compliance to diuretics.
Cost
When taking into account French social security reim-
bursement rate, NIV cost was 63.16€ per week and
CPAP cost was 18€ per week. This switch may allow an
economy of 2348€ per year per patient.
NIV failure
When analyzing the characteristics of the patients failing
NIV, according to Salord’s criteria: more than 30% of
recording time spent below 90% saturation or paCO2 >
45 mm Hg; BMI was the only factor associated with
NIV failure (p = 0.014) (Table 6).
Discussion
This prospective open trial, testing the feasibility of a
protocol switching NIV to CPAP in stable patients in
real life conditions, suggests the possibility of this switch
in patients suffering from OHS with an AHI ≥ 15/h and
without pulmonary obstructive disease. In these condi-
tions, we reported no significant treatment effect differ-
ences between before and after the switch to CPAP in
diurnal and nocturnal alveolar gas exchange, mean AHI,
mean compliance, quality of sleep and quality of life. In
addition, 80% of patients preferred CPAP over NIV.
The pathophysiology of OHS is complex and multifac-
torial. Eventually leading to chronic, diurnal hypercapnia
resulting from an imbalance between apnea and inter-
apnea periods and deficiency of the compensatory mech-
anisms to unload the carbon dioxide in excess [17, 18].
This suggests the need to determine different pheno-
types of OHS, and therefore adapt therapeutic interven-
tion according to the phenotype. Therefore we have
chosen in this trial, to exclude from the study, patients
with an AHI < 15/h, speculating that CPAP mechanism
to treat hypoventilation was mostly due to the correction
of apneas and hypopneas. Indeed, if CPAP is not
Fig. 2 Flow chart. Definition of abbreviations: OHS: Obesity Hypoventilation Syndrome; FEV1: Forced Expiratory Volume in 1 s; FVC: Forced Vital
Capacity; NIV: Non Invasive Ventilation; CPAP: Continuous Positive Airway Pressure; AHI: Apnea Hypopnea Index
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intrinsically the most efficient treatment of
hypoventilation, it is still effective on most of the patho-
physiological mechanisms leading to OHS by decreasing
upper airways resistance, increasing central response to
hypercapnia and hypoxemia [19, 20], increasing lung
volumes, treating atelectasis, decreasing intrinsic PEEP
[21]. This is the reason why CPAP is efficient in most
patients with OHS associated with OSA.
Two prospective randomized trials have compared the
efficacy of CPAP and NIV in patients with OHS [5, 11].
These two prospective studies corroborate the fact that
patients with OHS and concomitant OSA can be treated
with CPAP. Piper and colleagues did not find a signifi-
cant difference, at three months, in daytime paCO2
between the two groups NIV and CPAP [11]. However
in this study, nine of the 45 patients initially selected
were excluded from the trial, due to persisting nocturnal
hypoxemia or nocturnal hypercapnia on the first night
of CPAP titration. Treating hypoventilation in some
phenotypes may take up to a few weeks [22], excluding
patients after one night of CPAP titration is debatable.
Masa and colleagues confirmed the absence of a signifi-
cant difference between NIV and CPAP, at two months,
in diurnal paCO2 [5]. However, only NIV and not CPAP
significantly improved paCO2 compared to the control
group. An improvement was only noted for patients
Table 1 Baseline characteristics
Baseline characteristics n = 15
Sex (male) 5 (33.3%)
Age (years) 68.8 ± 11.2
BMI (kg/m2) 41.7 ± 7.16
Neck circumference (cm) 43.6 ± 4.5
Waist/Hip ratio 0.95 ± 0.08
pH on ABG before initiating NIV 7.38 ± 0.06
paCO2 on ABG before initiating NIV (mmHg) 57.7 ± 7.6
paO2 on ABG before initiating NIV (mmHg) 62.6 ± 18.8
HCO3- before initiating NIV (mmol/L) 31.8 ± 5.1
Actual or past smokers 7 (46.7%)
Pack per year 38.1 ± 30.9
Cardiovascular comorbidities 13 (86.7%)
Hypertension 12 (80%)
Dyslipidemia 12 (80%)
Diabetes 9 (60%)
Cardiac disease 12 (80%)
Ischemic cardiac disease 5 (33.3%)
Cardiac arrhythmia 5 (33.3%)
LVEF (%) 56 ± 14.3
Diastolic dysfunction 8 (61.5%)
Diagnosis made during an exacerbation 12 (80%)
Data are expressed in n (%) and mean ± standard deviation
Definition of abbreviations: BMI body mass index, ABG arterial blood gas, NIV
non invasive ventilation, LVEF left ventricular ejection fraction
Table 2 Wash out period: pulmonary function tests and
polygraphy
PFT and Polygraphy (during withdrawal) n = 15
FEV1/FVC (%) 79.5 ± 7.4
FEV1 (%) 69.2 ± 16.4
FVC (%) 70.2 ± 17.3
AHI (n/h) 53.5 ± 26.9
RT < 90% (%) 21.8 ± 24.2
ODI≥ 4% (n/h) 42.1 ± 39.5
Data are expressed in mean ± standard deviation
Definition of abbreviations: PFT pulmonary function test, FEV1 forced
expiratory volume in 1 s, FVC forced vital capacity, AHI apnea hypopnea index,
RT < 90% percentage of recording time below 90% saturation, ODI oxygen
desaturation index
Table 3 NIV and CPAP settings
NIV and CPAP settings n = 15
NIV mode ST
NIV EPAP (cm H2O) 7.7 ± 1.8
NIV IPAP (cm H2O) 18.3 ± 3
NIV RR (n/min) 13.9 ± 1.8
NIV VT (ml) 508.3 ± 264
CPAP EPAP (cm H2O) 9.8 ± 1.4
Oronasal mask 10 (66.7%)
Nasal mask 3 (20%)
Nasal pillows 2 (13.3%)
Data are expressed in mean ± standard deviation and n (%)
Definition of abbreviations: NIV non invasive ventilation, CPAP continuous
positive airway pressure, EPAP expiratory positive airway pressure, IPAP
inspiratory positive airway pressure RR respiratory rate, VT tidal volume
Table 4 Measured data with NIV and one month after the
switch to CPAP
Measured data NIV CPAP P value
Pa CO2 (mm Hg) 40.4 ± 5.1 40.9 ± 6.7 0.323
Pa O2 (mm Hg) 73.3 ± 8.8 74.4 ± 8.8 0.235
pH 7.43 ± 0.04 7.43 ± 0.03 0.508
HCO3 (mmol/L) 26.3 ± 3.14 26.6 ± 3.6 0.511
RT < 90% (%) 28.1 ± 27.2 20.5 ± 25.2 0.218
ODI≥ 4% (n/h) 11.92 ± 17.31 10 ± 9.41 0.285
Transcutaneous pCO2 (mm Hg) 49.9 ± 10.12 48.4 ± 5.14 0.534
AHI (n/h) 5.99 ± 10.96 5.49 ± 7.84 0.334
Leaks (L/sec) 3.8 ± 10.09 2.9 ± 6.1 0.844
Compliance (h) 6.73 ± 2.66 6.8 ± 2.27 0.766
Data are expressed in mean (standard deviation)
Definition of abbreviation: NIV non invasive ventilation, CPAP continuous
positive airway pressure, RT < 90% percentage of recording time below 90%
saturation, ODI oxygen desaturation index, AHI apnea hypopnea index
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using CPAP more than 4 h per night. Moreover, the
authors found a significant difference, favoring NIV, on
the 6 min’ walk test and respiratory function tests.
The heterogeneity in responses to CPAP, led some
studies to try to define phenotypes of OHS and predictor
factors of CPAP failure. Therefore, patients exhibiting a
higher BMI, a higher percentage of recording time below
90% saturation, a lower AHI, or a decreased forced vital
capacity could be at higher risk of CPAP failure, even
though these predictor factors are not constantly found
in all studies [8–10] . In our study, we found that only
BMI had a significant association with CPAP or NIV
failure (Table 6). When using the two criteria defining
failure in Salord and colleagues study [10] (more than
30% of recording time spent below 90% saturation or
paCO2 > 45 mm Hg), in our study 8/15 patients would
Fig. 3 Measurement of mean AHI; diurnal and nocturnal alveolar gas exchange parameters and mean compliance, in 15 patients, with NIV and
one month after the switch to CPAP. Definition of abbreviations: NIV: Non Invasive Ventilation; CPAP: continuous positive airway pressure; AHI:
Apnea Hypopnea Index; RT < 90% spO2: percentage of recording time below 90% saturation; NS: no significant difference p > 0.05
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be categorized as NIV failure and 7/15 as CPAP failure.
Interestingly, the seven patients failing CPAP were the
same patients who were failing NIV before the switch.
We do not think this failure can be attributed to NIV or
CPAP settings in our study. Mean EPAP was 8 cm H2O,
mean IPAP was 18 cm H2O, back-up RR was 14 cycles/
min, all NIV were in ST mode. Concerning CPAP, mean
EPAP was 9.8 cm H2O. These pressures are concordant
with previous trials [5, 11].
Our study has some limitations. First of all it can be
argued that the sample size in our study (15 patients)
could be insufficient to detect a significant difference after
the switch to CPAP, and that this absence of difference
could be due to a lack of power. This study does not have
the pretention to assert the absence of difference between
NIV and CPAP at a larger scale, but describes a feasible
protocol for most sleep clinic, to switch stable patients
with OHS from NIV to CPAP. As suggested by our
preliminary results, for some patients, the switch of NIV
to CPAP can be deleterious emphasizing the need for a
careful monitoring. A second limitation is that the results
of our study can only be extended to patients with OHS
and concomitant OSA with AHI ≥ 15/h, without obstruct-
ive pulmonary diseases, and cannot be used when treating
patients in an acute state or with mild OSA. These drastic
selection criteria aimed at targeting CPAP responders’
phenotypes and the limited number of patients included
in the study could partly explain the stable diurnal capnia
after the switch to CPAP in all of our patients. The
Table 5 ESS, PSQI and its components, SRI and its subscales
scores with NIV and one month after the switch to CPAP
Scores NIV CPAP P value
ESS 8.21 ± 5.54 4.29 ± 3.43 0.004*
PSQI 6.86 ± 4.77 6.14 ± 3.65 0.311
Componant 1 1.07 ± 0.92 0.86 ± 0.53 0.500
Componant 2 0.79 ± 1.37 1.29 ± 1.27 0.250
Componant 3 0.93 ± 0.83 0.93 ± 1.07 1
Componant 4 0.5 ± 0.85 0.57 ± 0.85 0.531
Componant 5 1.29 ± 0.61 1.21 ± 0.43 1
Componant 6 1.21 ± 1.48 0.43 ± 1.09 0.125
Componant 7 1 ± 1.18 0.86 ± 1.03 0.766
SRI 62.4 ± 19.46 66.5 ± 17.32 0.153
SRI RC 70 ± 21.61 71.87 ± 21.58 0.529
SRI PF 48.61 ± 28.33 46.13 ± 29.17 0.404
SRI AS 54.83 ± 28.80 64.54 ± 22.04 0.135
SRI SF 70.83 ± 21.30 75 ± 19.81 0.682
SRI ANX 69.67 ± 16.74 70.14 ± 18.02 0.968
SRI WB 61.31 ± 28.63 73.21 ± 21.89 0.240
SRI SR 61.54 ± 23.52 64.38 ± 22.25 0.675
Data are expressed in mean (standard deviation)
Definition of abbreviations: NIV non invasive ventilation, CPAP continuous
positive airway pressure, ESS epworth sleepiness scale, PSQI Pittsburgh sleep
quality index, SRI severe respiratory insufficiency questionnaire, RC respiratory
complaints, PF physical functioning, AS attendant symptoms, SF social
functioning, ANX anxieties, WB well being, SR social relationships
*means significance with p value < 0.05
Fig. 4 Changes in ESS, PSQI and SRI scores one month after the switch to CPAP. Definition of abbreviations: NIV: Non Invasive Ventilation; CPAP:
Continuous Positive Airway Pressure; ESS: Epworth Sleepiness Scale, PSQI: Pittsburgh Sleep Quality Index; SRI: Severe Respiratory Insufficiency
questionnaire; NS: no significant difference; *: significant difference p < 0.05
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treatment of patients with OHS with pure hypoventilation
and without OSA, is seldom discussed in scientific litera-
ture, and these patients still benefit from NIV in most
teams [23]. For ethical reasons, we decided not to switch
to CPAP, patients with mild OSA (AHI < 15/h), to not de-
prive these patients with previous acute exacerbation from
an effective therapy.
To eliminate NIV persistent effect, we introduced in
the protocol, a withdrawal from NIV for seven nights be-
fore starting CPAP, and reevaluated patients more than a
month after starting CPAP. It is possible that not all per-
sistent effects attributable to NIV were eliminated by
this withdrawal [24]. An ideal protocol would have been
to randomize patients into three groups: one group pur-
suing NIV, one group switching to CPAP and one group
stopping ventilation; but this protocol did not seem eth-
ical for patients withdrawn from ventilation, considering
that a higher mortality rate has been reported in un-
treated patients with OHS [4, 6, 7]. In our study, 12 out
of 15 patients were diagnosed with OHS and started on
NIV, following an episode of exacerbation. This raises
the question as to whether the diagnosis of OHS was
made in excess in patients with normocapnic OSA
undergoing an exacerbation. This assertion is however
contradicted by the fact that nine out of the 12 patients
diagnosed with OHS following an exacerbation, had high
bicarbonates level (HCO3- > 28 mmol/l), in favor of
chronic hypercapnia [25]. When measuring the AHI, we
used the built-in software available in the NIV and the
CPAP. Although the accuracy of these systems is debat-
able, recent studies are in favor of a good reliability of
these built-in softwares [26].
Conclusion
In conclusion, this preliminary study showed in real life
conditions, the possibility of a systematic switch of NIV
to CPAP in most stable patients with OHS and a
concomitant OSA, with similar efficacy on diurnal and
nocturnal alveolar gas exchange, quality of life and qual-
ity of sleep. These results need to be confirmed by a lar-
ger trial that could also evaluate the clinical
consequences of this switch in the longer term, espe-
cially cardio-vascular consequences.
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